530057 — Vivanza Biosciences Income Statement
0.000.00%
- IN₹91.60m
- IN₹152.28m
- IN₹278.35m
- 17
- 45
- 14
- 11
Annual income statement for Vivanza Biosciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 96.2 | 98.9 | 104 | 178 | 278 |
Cost of Revenue | |||||
Gross Profit | 3.29 | 7.36 | 7.47 | 13 | 18.8 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 99.6 | 98 | 105 | 171 | 268 |
Operating Profit | -3.41 | 0.858 | -0.898 | 6.6 | 10.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.06 | 1.23 | 3.33 | 7.17 | 6.95 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2.06 | 0.753 | 3.33 | 5.98 | 5.47 |
Net Income Before Extraordinary Items | |||||
Net Income | -2.06 | 0.753 | 3.33 | 5.98 | 5.47 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.06 | 0.753 | 3.33 | 5.98 | 5.47 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.051 | 0.019 | 0.083 | 0.15 | 0.14 |